Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Understanding the Impact of Biotech Innovations on Healthcare

Sep 01, 2025

Revolutionizing Healthcare with Biotech Innovations

The field of biotechnology is at the forefront of transforming healthcare, offering groundbreaking solutions that promise to improve patient outcomes and streamline medical processes. From personalized medicine to regenerative therapies, biotech innovations are reshaping how we approach disease prevention, diagnosis, and treatment.

biotechnology healthcare

Personalized Medicine: Tailoring Treatment to Individuals

One of the most significant impacts of biotech in healthcare is the advent of personalized medicine. By leveraging genetic information, healthcare providers can tailor treatments to individual patients, ensuring more effective and targeted approaches. This personalized strategy not only enhances treatment efficacy but also reduces the risk of adverse side effects.

For instance, cancer patients can benefit from precision medicine that targets specific genetic mutations in their tumors. This approach allows for the development of therapies that are highly specific to the patient's condition, increasing the likelihood of successful outcomes.

Regenerative Medicine: Healing and Restoring Function

Regenerative medicine is another promising area within biotechnology that focuses on repairing and regenerating damaged tissues and organs. Techniques such as stem cell therapy and tissue engineering are paving the way for innovative treatments that can restore function and improve quality of life for patients with chronic conditions.

stem cell therapy

These therapies hold potential for conditions previously deemed irreversible, such as spinal cord injuries or heart diseases. By harnessing the body's natural healing processes, regenerative medicine offers hope for long-term recovery and improved patient health.

Biotechnology in Diagnostics: Early Detection and Prevention

Biotech innovations are also revolutionizing diagnostic procedures, enabling early detection and prevention of diseases. Advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, allow for faster and more accurate disease identification.

Early detection is crucial in managing chronic diseases like diabetes and cardiovascular conditions. By identifying these diseases at an early stage, healthcare providers can implement preventive measures and interventions that significantly improve patient outcomes.

diagnostic technology

The Role of Biotech in Vaccine Development

The COVID-19 pandemic underscored the critical role of biotechnology in vaccine development. The rapid creation and deployment of mRNA vaccines were made possible through decades of biotech research. This breakthrough not only provided a swift response to a global crisis but also opened new avenues for vaccine development against other infectious diseases.

Biotech innovations continue to advance vaccine technology, offering hope for more effective and accessible vaccines worldwide. This progress is vital for global health security and preparedness against future pandemics.

Challenges and Future Prospects

Despite the remarkable progress, the integration of biotech innovations into healthcare systems poses challenges. Ethical considerations, regulatory hurdles, and cost barriers are ongoing concerns that need addressing to fully realize the potential benefits.

Nevertheless, the future prospects of biotechnology in healthcare are promising. Continued research and collaboration between scientists, healthcare providers, and policymakers will be essential in overcoming these challenges and advancing medical science.

future of biotechnology

As biotech innovations continue to evolve, they will undoubtedly play an increasingly vital role in shaping the future of healthcare. By embracing these advancements, we can look forward to a new era of medicine characterized by improved patient care, disease prevention, and overall health outcomes.